奥浦迈(688293) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥83,678,844.28, representing a 4.98% increase compared to ¥79,706,760.24 in the same period last year[5] - Net profit attributable to shareholders decreased by 25.08% to ¥14,668,012.82 from ¥19,578,569.83 year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 33.06% to ¥10,799,748.66 compared to ¥16,133,022.74 in the previous year[5] - The company reported a basic earnings per share of ¥0.13 for Q1 2025, down from ¥0.17 in Q1 2024[26] - Total revenue for Q1 2025 reached ¥83,678,844.28, a 4.0% increase from ¥79,706,760.24 in Q1 2024[25] - Net profit for Q1 2025 was ¥14,550,763.03, a decrease of 25.0% compared to ¥19,403,531.33 in Q1 2024[26] - Total operating costs increased to ¥62,185,716.32 in Q1 2025, up 5.0% from ¥58,919,501.84 in Q1 2024[25] - Operating profit for Q1 2025 was ¥22,473,249.81, slightly down from ¥23,105,634.60 in Q1 2024[25] - The total comprehensive income for Q1 2025 was ¥14,543,974.63, a decrease from ¥19,414,232.69 in Q1 2024[26] Cash Flow and Assets - The net cash flow from operating activities significantly improved to ¥43,308,029.62, a 665.63% increase from ¥5,656,507.94 in the same period last year[5] - The company's customer payment amount increased significantly by 47.73% compared to the same period last year, reflecting improved cash flow and collection efficiency[18] - The total current assets as of March 31, 2025, amounted to CNY 1,609,371,269.94, an increase from CNY 1,549,076,630.82 as of December 31, 2024[21] - The company's cash and cash equivalents as of March 31, 2025, were CNY 737,059,898.05, down from CNY 891,143,542.80 as of December 31, 2024[21] - Cash flow from operating activities for Q1 2025 was ¥43,308,029.62, significantly higher than ¥5,656,507.94 in Q1 2024[28] Research and Development - Research and development expenses totaled ¥12,114,331.01, marking a 56.51% increase from ¥7,740,448.49 year-on-year, accounting for 14.48% of operating revenue[5] - Research and development expenses increased to ¥12,114,331.01 in Q1 2025, up from ¥7,740,448.49 in Q1 2024, reflecting a focus on innovation[25] Investment and Market Position - The company reported a significant increase in investment income by 204.88% due to the maturity of several financial products in Q1 2025[8] - The company experienced a 53.73% increase in credit impairment losses, attributed to macroeconomic fluctuations and changes in customer conditions[8] - The company maintains a strong market position in cell culture products, which are expected to continue driving revenue growth due to sustained market demand[14] - CDMO service revenue increased by 27.11% compared to the previous year, indicating strong performance despite market challenges[15] Shareholder Information - The total number of common shareholders at the end of the reporting period was 3,027[10] - The largest shareholder, Xiao Zhihua, holds 24.90% of the shares, while the top ten shareholders collectively hold significant stakes[10] - The actual controllers of the company are Xiao Zhihua and He Yunfen, who together control 32.06% of the shares[12] Operational Developments - The company implemented a share buyback program in Q4 2024, which concluded in October 2024, resulting in no further buybacks in Q1 2025[8] - The company’s wholly-owned subsidiary, Aopumai Biotechnology (Taicang) Co., Ltd., officially commenced operations, focusing on the research and production of agarose products[18] - The company’s U.S. subsidiary's laboratory has been officially put into use, focusing on the development of culture media to support market expansion in the U.S.[19] - The company successfully passed the ISO 9001:2015 quality management system audit with "0 corrective actions," enhancing its market competitiveness[19] - The company is expected to receive the Qualified Person (QP) compliance statement in the second quarter, which will facilitate its entry into the EU market[19] Asset and Liability Overview - Total assets at the end of the reporting period were ¥2,307,695,080.00, a 0.94% increase from ¥2,286,250,982.16 at the end of the previous year[5] - The company’s total liabilities as of March 31, 2025, were CNY 196,632,223.68, up from CNY 190,970,352.87 as of December 31, 2024[23] - The company’s total assets reached CNY 2,307,695,080.00 as of March 31, 2025, compared to CNY 2,286,250,982.16 as of December 31, 2024[23]